Forrester Announces Full Conference Agenda For Technology & Innovation Summit EMEA 2024
Forrester (Nasdaq: FORR) today announced the full conference agenda for Technology & Innovation Summit EMEA, held in London and digitally, October 9–11, 2024. While the potential of generative AI (genAI) to enhance efficiency and innovation is evident, tech leaders must strike the right balance, leveraging emerging technologies like automation and genAI to fuel innovation while also making sure to avoid stifling it. They need to understand where AI can make the most significant impact and identify the necessary resources for effective implementation.
At this year’s Technology & Innovation Summit EMEA, technology, data and analytics, and cybersecurity leaders will have insight into new research and learn best practices to achieve high-performance IT, understand the ethical, safe, and secure ways to take advantage of new technologies that are fundamental to building trust with their customers, and assess how to use AI as a catalyst for innovation and change.
Noteworthy keynotes and sessions include:
- Generative AI As A Forcing Factor For Change. In this keynote, technology leaders will learn how to maximise their investment in genAI to scale beyond a single use case.
- Unleash Your Potential With High-Performance IT. This keynote will cover how to align and adapt to changing business dynamics with high-performance IT.
- Embrace Trust, Adaptivity, And Alignment for AI Success. In this keynote, leaders will understand how to address the AI bottleneck by breaking down operational and data silos.
- A Fun (Yes, Really) Crash Course In EU AI Act Compliance. This session will reveal which initiatives and capabilities to prioritise and outline a dedicated roadmap to help tech leaders prepare for the impending EU AI Act.
- Staying Resilient In A Fluid Technology And Threat Landscape. In this keynote, cybersecurity leaders will explore how to approach AI practically, balancing risk and opportunity.
- AI, Low-Code, And The End Of Software Development As We Know It. This keynote will discuss the impact of genAI on the software development lifecycle and explore the emergence of application generation platforms infused with both predictive and generative AI.
“Tech, data, and security leaders in Europe are under tremendous pressure to deliver on AI investments,” said Pascal Matzke, Forrester VP and research director and T&I EMEA event host. “At Technology & Innovation EMEA, leaders will learn how to overcome common obstacles associated with the adoption of genAI and how leaders can effectively steer, align, and motivate their business to successfully scale their genAI initiatives.”
In-person attendees will experience facilitated discussions, consulting workshops, and special programmes, including the Women’s Leadership Programme; the Executive Leadership Exchange, an exclusive programme targeted at C-level leaders; and several diversity and inclusion sessions. Digital attendees will have access to all conference sessions and sponsors via the event platform.
Resources:
- Register to attend Forrester’s Technology & Innovation Summit EMEA 2024.
- View the full agenda and speakers for Technology & Innovation Summit EMEA 2024.
- Follow @Forrester and #ForrTech for updates.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the centre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; and the shared wisdom of our clients. To learn more, visit Forrester.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903845085/en/
Contacts
Press contacts:
Hannah Segvich
hsegvich@forrester.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ArcanaBio Secures Funding from BioInnovation Institute to Revolutionize Healthcare with new Ultra-Rapid Liquid Biopsy Technology9.9.2024 08:15:00 CEST | Press release
ArcanaBio, a pioneering biotech company, is proud to announce its selection for funding by Denmark’s BioInnovation Institute (BII), supported by the Novo Nordisk Foundation. ArcanaBio will join BII’s Deep Tech Lab – Quantum program in Copenhagen from September 2024. “We are honoured to receive funding and to be selected to join this prestigious quantum initiative,” said Kristjan Gunnarsson, CEO of ArcanaBio. “We are at the forefront of a new biosensor revolution with a patent-pending, label-free detection technology that has been a long-sought-after advancement in proteomics. Our novel platform has potential both to enable testing laboratories to offer a wider range of biomarker services at lower cost and empower individuals to proactively monitor their health by integrating frequent, reference-quality testing into their lives.” “The goal here is to rethink diagnostics. Building a new capability to track proteome dynamics can provide powerful real-time and predictive insights into heal
Saint-Denis Hospital Center in France Implements Masimo SafetyNet ® Telemonitoring to Facilitate Early Discharge of Premature Newborns from the Hospital9.9.2024 08:00:00 CEST | Press release
Masimo (NASDAQ: MASI) today announced that Saint-Denis Hospital Center is adopting the use of the Masimo SafetyNet® cloud-based telemonitoring platform as part of an experimental mobile neonatology unit aimed at facilitating earlier discharge of premature newborns from the ICU to the home. Launched in February, this pioneering project allows vulnerable neonates to return home safely to their families while remaining under the close supervision of the hospital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240908136612/en/ Masimo SafetyNet® and Saint-Denis Hospital Center, Delafontaine (France) (Photo: Business Wire) Masimo SafetyNet offers a streamlined approach to remote patient management that can be scaled and tailored to each patient’s unique care needs, offering wireless continuous monitoring and spot-check devices, customizable CarePrograms™ with symptom reporting, and a secure in-hospital clinical portal that allows
Epsilogen Completes £12.5 Million Series B Financing Expansion9.9.2024 08:00:00 CEST | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the completion of a £12.5 million Series B expansion financing bringing the Series B total to £43.25 million. This financing will fund the delivery of clinical Proof of Concept for lead asset MOv18 IgE in a phase Ib trial featuring platinum-resistant ovarian cancer (PROC) as well as further development of the company’s IgE-based pipeline. The financing was entirely conducted by existing investors including British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund and ALSA Ventures. MOv18 IgE is the first therapeutic IgE antibody to enter the clinic. This first-in-class antibody targets folate receptor alpha (FRα), an antigen present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. In a phase I trial, MOv18 IgE was found to be safe and well tolerated with initial signs of clinical activity also se
BeiGene Highlights TEVIMBRA ® Data in Lung and Gastrointestinal Cancers at ESMO 20249.9.2024 07:00:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data for TEVIMBRA® (tislelizumab) at the European Society of Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, September 13-17, 2024. BeiGene has seven abstracts accepted at ESMO 2024, with one selected for the special session revisiting the ESMO Virtual Plenary held in February 2024. New Data Add to Evidence for TEVIMBRA Across Multiple Disease States As an encore to the ESMO plenary, interim results from the RATIONALE-315 study show the statistically significant event-free survival (EFS) and trend for overall survival (OS) benefit favoring neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab vs. placebo plus chemotherapy with adjuvant placebo for patients with resectable non-small cell lung cancer (NSCLC) (session #VP1-2024, Sept. 13 from 4:17-4:29 p.m. CEST). These results further reinforce the data presented at ESMO 2023 showing major p
Nytt i Personio: Bättre medarbetarinsikter och prestationsbedömningar, anpassade arbetsflöden och löneutbetalningar ökar effekten för HR-team9.9.2024 01:01:00 CEST | Pressmeddelande
Personio, Europas ledande HR-systemföretag för små och medelstora företag, har idag presenterat en rad förbättringar utformade för att minska administrationen för HR-team så att de kan fokusera mer på att leverera resultat för sina organisationer. Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20240908703783/sv/ Personio releases a series of advancements to further alleviate the burden of manual and time-intensive administrative tasks for HR teams. (Photo: Business Wire) Dessa förbättringar annonseras samtidigt som lanseringen av Personios senaste undersökning, Workforce Pulse 2024: Så löser du personal- och engagemangsrelaterade utmaningar. Den visar att 32% av HR-beslutsfattarna anser att den viktigaste utmaningen som deras organisationer måste ta itu med under det kommande året är att behålla talanger. Detta följs av 29% som anser att man bör fokusera på att förbättra medarbetarnas välbefinnande och 27% som säger
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom